Prostatepedia Weekly 9.28.18
Prostatepedia Weekly 9.21.18
Prostatepedia Weekly 9.14.18
Low Testosterone and Prostate Cancer: Is the Protection Real? - European Urology
Prostate Cancer Screening: No Effect on Overall Mortality:
Screening for prostate cancer may result in a small absolute benefit in
disease-specific mortality over 10 years but does not improve overall
mortality.
Gallium-68 PET/CT scans prior to first-line treatment of some men with prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK:
A newly-reported set of data from an Australian clinical research team
has now shown that 68Ga PSMA PET/CT scans changed the staging and the
management of men after initial diagnosis and prior to f…
ASCO endorses AUA/ASTRO/SUO guidelines on treatment of localized prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK:
We are delighted to note that the American Society of Clinical Oncology
(ASCO) has now endorsed 66 of the 68 guidelines issued in April 2017 on
the treatment of localized prostate cancer by a joint…
Gallium-68 PET/CT scans prior to first-line treatment of some men with prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK:
A newly-reported set of data from an Australian clinical research team
has now shown that 68Ga PSMA PET/CT scans changed the staging and the
management of men after initial diagnosis and prior to f…
Computer-aided
classification of prostate cancer grade groups from MRI images using
texture features and stacked sparse autoencoder - ScienceDirect: A
novel method to determine the Grade Group (GG) in prostate cancer (PCa)
using multi-parametric magnetic resonance imaging (mpMRI) biomarkers is
inv
Study: Hormone Therapy Can Make Prostate Cancer Worse in Some Patients | Cooking with Kathy Man:
Scientists at Cedars-Sinai have discovered how prostate cancer can
sometimes withstand and outwit a standard hormone therapy, causing the
cancer to spread. Their findings also point to a simple blo…
What prostate cancer awareness means to Dr. Alicia Morgans | THE "NEW" PROSTATE CANCER INFOLINK:
Alicia Morgans, MD, MPH, is a medical oncologist who specializes in
prostate cancer management at Northwestern University Feinberg School of
Medicine in Chicago, Illinois, where she is an associate
Imaging of distant metastases of prostate cancer | SpringerLink:
The detection of distant metastases at the initial diagnosis of
prostate cancer (PCa) establishes the treatment approach and has a
prognostic value, nevertheless it is not well established. Since...
Addressing Challenges to Adopting MRI for Prostate Cancer Screening | Newsroom | Weill Cornell Medicine:
Magnetic resonance imaging (MRI) may not be the best diagnostic choice
universally for all men suspected of having prostate cancer, according
to researchers at Weill Cornell Medicine and NewYork-Presbyterian.
Hypothetical cost savings associated with “observation” for low-risk prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK:
A newly published article in JAMA Oncology has reported hypothetical
costs savings to Medicare of $320 million over a 3-year time frame if
men of > 70 years with low-risk prostate cancer are sim…
Direct mechanical characterization of prostate tissue—a systematic review - Kelly - - The Prostate - Wiley Online Library
But annual, mass, population-based PSA screening really works (or does it?) | THE "NEW" PROSTATE CANCER INFOLINK:
A new and potentially controversial article in Urology (the “Gold
Journal”) has just suggested that regular, mass, population-based
screening of men for risk of prostate cancer every 12…
Complications of Androgen Deprivation Therapy in Men With Prostate Cancer: Page 2 of 2 | Cancer Network:
This article summarizes the key side effects associated with ADT for
the treatment of prostate cancer and discusses strategies to optimize
management.
New trial (S1802) for treatment of men with newly diagnosed, metastatic prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK:
Earlier this month we had mentioned hearing about a new trial to
explore whether local ablation of the primary tumor could improve the
outcomes of men initially diagnosed with metastatic prostate c…
68Ga-PSMA-11 PET: Better at Detecting Prostate Cancer than Multiparametric MRI? | Radiology
Dismissing Reduced Abiraterone Dose Is 'Absolutely Wrong':
By taking a prostate cancer drug with food, patients can use a quarter
of the dose. But an editorial dismissed the idea, which angered a
prominent expert.
Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens - E. David Crawford: Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens
Active surveillance for localized prostate cancer. Nationwide, observational study - The Journal of Urology: The objective of this study was to investigate nationwide survival outcomes in men
with localized prostate cancer managed on active surveillance.
What to Expect When Active Surveillance Leads to Prostatectomy | Medpage Today: High-risk features in 39% of prostate specimens at surgery
Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance - The Journal of Urology: Active surveillance (AS) for intermediate-risk prostate cancer (PCa) is controversial.
Many AS programs are limited to grade group (GG) 1 (Gleason 6) and PSA<10 ng/ml. However,
recent guidelines state that AS can be considered for limited GG2 (Gleason 3+4), despite
limited data on outcomes. Our objective was to compare prostatectomy outcomes between
subgroups of intermediate-risk versus low-risk PCa.
Worth
a local treatment? – Analysis of modern radiotherapy concepts for
oligometastatic prostate cancer | Radiation Oncology | Full Text:
Prostate cancer (PCA) is the most-prevalent non-skin cancer in men
worldwide. Nevertheless, the treatment of oligometastatic, especially
lymph-node (ln) recurrent, PCA remains elusive. The aim of our study was
to provide insights in radiotherapy (RT)-treatment of recurrent PCA
exhibiting ln- or osseous (oss)-oligometastases. Between April 2012 and
April 2017, 27 oligometastatic PCA patients (19 ln and 8 single oss)
were treated with RT at our institution. The metastasis-free survival
(MFS) was 24.8 m (22.0–36.0 m) and 25.4 m (23.9–28.1 m) for the ln- and
oss-subgroup resulting in 1-year MFS of 75.4 and 100% and 2-year MFS of
58.7 and 83.3% for ln- and oss-metastatic patients, respectively. Of
notice, none of the recurrences for ln-patients was in the RT-field,
constituting a local control of 100%. Within the ln-group, pre-RT
median-PSA was 2.6 ng/ml, median post-RT PSA was 0.3 ng/ml, which was
significant (p = 0.003). Median biochemical-free survival (bfS) was
12.2 m. PCA that was initially confined to the prostate had a better bfS
(p < 0.001) and MFS (p = 0.013). The oss-group had a median PSA
of 4.9 ng/ml pre-treatment which dropped to a median value of 0.14 ng/ml
(p = 0.004). To
ANO7 Gene Linked to Aggressive Prostate Cancer | Cancer Network:
By elevating the expression of ANO7, a potential prostate cancer
susceptibility gene, it may be possible to predict disease severity and
outcome.
Total
Medicare Costs Associated With Diagnosis and Treatment of Prostate
Cancer in Elderly Men | Oncology | JAMA Oncology | JAMA Network:
This large cohort study uses the SEER-Medicare database to evaluate the
Medicare costs associated with diagnosis and treatment of nonmetastatic
prostate cancer in men 70 years or older.
High Anxiety with Active Surveillance in Prostate Cancer? Not Really | Medpage Today: In my case, the first week after diagnosis was bad, but that was it
External Validation of Prostate MRI QCAD/Lyon - Full Text View - ClinicalTrials.gov: External Validation of Prostate MRI QCAD/Lyon - Full Text View.
Open- Label
Trial of Sipuleucel-T Administered to Active Surveillance Patients for
Newly Diagnosed Prostate Cancer - Full Text View - ClinicalTrials.gov:
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance
Patients for Newly Diagnosed Prostate Cancer - Full Text View.
More Doctors Say Men Should Think Twice about Prostate Cancer Screening | Cooking with Kathy Man:
Lisa Rapaport wrote . . . . . . . . . Most men shouldn’t get routine
prostate cancer screening because the potential benefits are small and
there are clear harms, an international panel of experts …
An Integrative Approach to Prostate Cancer | The Journal of Alternative and Complementary Medicine
Complications of Androgen Deprivation Therapy in Men With Prostate Cancer | Cancer Network:
This article summarizes the key side effects associated with ADT for
the treatment of prostate cancer and discusses strategies to optimize
management.
Ac-225-PSMA-617: another update | THE "NEW" PROSTATE CANCER INFOLINK:
One of the more exciting new developments in radiopharmaceuticals for
metastatic prostate cancer has been the development of alpha-particle
emitters attached to PSMA ligands. We previously reported…
Optimal Control to Develop Therapeutic Strategies for Metastatic Castrate Resistant Prostate Cancer - ScienceDirect:
In metastatic castrate resistant prostate cancer (mCRPC), abiraterone
is conventionally administered continuously at maximal tolerated dose
until trea…
Ac-225-PSMA-617: another update | THE "NEW" PROSTATE CANCER INFOLINK:
One of the more exciting new developments in radiopharmaceuticals for
metastatic prostate cancer has been the development of alpha-particle
emitters attached to PSMA ligands. We previously reported…
Three-dimensional localization and targeting of prostate can... : Current Opinion in Urology:
d follow-up. However, the accuracy of MRI to detect clinically
significant disease is variable between different institutions. The role
of quality control initiatives to increase the concordance between
clinical-imaging–histopathological data and to improve accurate
targeting of the suspicious lesions cannot be overemphasized. This
article describes the approaches to correlate mpMRI findings with
histopathology and the role of multidisciplinary teams for quality
improvement and feedback interventions.
Recent findings
Validating
the mpMRI and image-targeted fusion biopsy findings with prostatectomy
specimen histopathology as the gold standard is essential for assessment
of the concordance between clinical-imaging–histopathological data.
Utilization of a MRI-derived patient-specific prostate mold enables a
direct comparison between histopathological versus imaging
characteristics of cancer foci in the same sectional plane of the
specimen versus MRI. Furthermore, ‘reverse fusion’ technology provides
the ability to audit the quality of targeting following fusion biopsy.
Summary
The development of a multidisciplinary team approach with group discussions, workflows to integrate and cor
MRI to guide biopsies or avoid biopsies? : Current Opinion in Urology:
of care for men with increased suspicion for prostate cancer, MRI with
or without targeted biopsy has been shown to reliably improve the
detection of clinically significant disease following a prior negative
biopsy. At the same time, there is a growing body of evidence to support
the use of MRI for diagnostic purposes in biopsy-naive patients, as
well for enrolling and monitoring men on active surveillance programs.
Summary
mpMRI
is an evolving technology with great promise for altering our approach
to prostate cancer diagnosis and surveillance. In conjunction with
targeted biopsies, MRI offers greater specificity for the detection of
clinically significant cancer and therefore may help to reduce
overdetection of indolent disease while minimizing the risks and
limitations of systematic biopsies.
No comments:
Post a Comment